# OnCo record darbepoetin-alfa (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/darbepoetin-alfa/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "darbepoetin-alfa" ;
  schema:name "Darbepoetin alfa"@en ;
  schema:description "Darbepoetin alfa (Aranesp) is a longer-acting version of erythropoietin given every one to three weeks to treat anaemia caused by chemotherapy, reducing transfusions but with the same warnings about clots and tumour growth as epoetin."@en ;
  schema:url <https://onco.cc/drugs/darbepoetin-alfa/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Darbepoetin_alfa> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=darbepoetin%20alfa>, <https://www.cancer.gov/about-cancer/treatment/drugs/darbepoetinalfa>, <https://www.ema.europa.eu/en/medicines/human/EPAR/aranesp> ;
  onco:status "approved" ;
  onco:tag "nci-list", "supportive" ;
  onco:modality "Hyperglycosylated recombinant erythropoietin (erythropoiesis-stimulating agent)" ;
  schema:alternateName "Aranesp" ;
  onco:approval "US 2001: Anaemia of chronic kidney disease", "US 2002: Anaemia due to concomitant myelosuppressive chemotherapy in non-myeloid malignancies", "EU 2001: Anaemia of chronic renal failure; symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy (Aranesp)" ;
  onco:related <https://onco.cc/drugs/epoetin-alfa/> ;
  onco:technologies <https://onco.cc/technologies/transfusion-support/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:trials <https://onco.cc/trials/nct00261313/>, <https://onco.cc/trials/nct00077311/>, <https://onco.cc/trials/nct02890602/> .